Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||0.22%||69.65||1.0%||$510.30m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.08%||205.22||1.9%||$451.66m|
|REGN||Regeneron Pharmaceuticals, Inc.||1.61%||635.09||2.7%||$406.05m|
|SNSS||Sunesis Pharmaceuticals, Inc.||2.38%||4.31||0.7%||$301.28m|
|EXAS||EXACT Sciences Corp.||3.12%||83.36||18.0%||$145.51m|
|BMRN||BioMarin Pharmaceutical, Inc.||2.23%||86.12||4.2%||$137.03m|
Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the bodyâ€™s immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the bodyâ€™s immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immune-therapy drugs which genetically engineer a patientâ€™s own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.